The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma
Authors
Keywords
CXCR2, SOCS-3, IL-6, IL-8, Microvessels, Angiogenesis, Renal cell carcinoma
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-03-05
DOI
10.1186/1471-2407-14-149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chemokine receptor CXCR2 is transactivated by p53 and induces p38-mediated cellular senescence in response to DNA damage
- (2013) Haiyang Guo et al. AGING CELL
- Interleukin-6 signaling pathway in targeted therapy for cancer
- (2012) Yuqi Guo et al. CANCER TREATMENT REVIEWS
- Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression
- (2012) Toshiki Oguro et al. EUROPEAN JOURNAL OF CANCER
- SOCS-1gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma
- (2012) Kota Iwahori et al. INTERNATIONAL JOURNAL OF CANCER
- Unknown
- (2012) Penelope Korkolopoulou et al. MOLECULAR MEDICINE
- The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue
- (2011) O Oladipo et al. BRITISH JOURNAL OF CANCER
- IGF-1 induced HIF-1α-TLR9 cross talk regulates inflammatory responses in glioma
- (2011) Sanchari Sinha et al. CELLULAR SIGNALLING
- Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: Correlation with IL-6, VEGF and microvessel morphometry
- (2011) Christina Piperi et al. CYTOKINE
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α
- (2010) Shintaro Tomita et al. CANCER SCIENCE
- CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis
- (2010) G. Yang et al. CLINICAL CANCER RESEARCH
- CXC receptor-2 knockout genotype increases X-linked inhibitor of apoptosis protein and protects mice from acetaminophen hepatotoxicity
- (2010) Bin Hu et al. HEPATOLOGY
- VHL and HIF signalling in renal cell carcinogenesis
- (2010) Marcella M Baldewijns et al. JOURNAL OF PATHOLOGY
- Host CXCR2-Dependent Regulation of Melanoma Growth, Angiogenesis, and Experimental Lung Metastasis
- (2009) S. Singh et al. CANCER RESEARCH
- Down-regulation of Suppressor of Cytokine Signaling-3 Causes Prostate Cancer Cell Death through Activation of the Extrinsic and Intrinsic Apoptosis Pathways
- (2009) M. Puhr et al. CANCER RESEARCH
- CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer
- (2009) Yoichi Matsuo et al. INTERNATIONAL JOURNAL OF CANCER
- Expression of Signal Transducer and Activator of Transcription 3 and Suppressor of Cytokine Signaling 3 in Urothelial Carcinoma
- (2009) Wan-Ting Huang et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- SOCS1 and SOCS3 in the control of CNS immunity
- (2009) Brandi J. Baker et al. TRENDS IN IMMUNOLOGY
- Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression
- (2008) E. C. Brantley et al. CLINICAL CANCER RESEARCH
- SOCS3 suppresses AP-1 transcriptional activity in neuroblastoma cells through inhibition of c-Jun N-terminal kinase
- (2007) Tizong Miao et al. MOLECULAR AND CELLULAR NEUROSCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started